Vitamin C trial EVITA shows fewer adverse events in pre-leukemia disorders

In the randomized EVITA trial, 109 people with CCUS or myelodysplastic syndrome took 1,000 mg of oral vitamin C daily for one year. The vitamin C group had fewer adverse events and, after about three years of follow-up, were more likely to be alive, though the result needs confirmation in a phase 3 study.

• 109 patients with CCUS or MDS took 1,000 mg of vitamin C daily for one year
• The vitamin C group had fewer adverse events than those on placebo
• After ~3 years of follow-up, vitamin C recipients were more likely to be alive
• No significant difference was found in expansion of abnormal blood cell clones